Navigation Links
Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Date:10/24/2013

he expansion will increase Regeneron's square footage on the campus by more than 40 percent and make it possible for Regeneron to create approximately 400 new full-time jobs in Westchester, where it currently employs more than 1,500.  With a total of over 2,200 employees, including nearly 700 in the Regeneron Industrial Operations and Product Supply group in Rensselaer, New York near Albany, Regeneron is the largest biotechnology company in New York State and one of the five largest in the world by market capitalization.

The 2013 Science survey sought to identify the companies with the best reputations as employers, based on 3,656 survey responses from readers of Science and other survey invitees.  Survey participants came from North America (81%), Europe (10%), and Asia/Pacific Rim (7%); over 80% worked in private industry.  Details of the rankings and survey results can be found in sciencecareers.org and will be featured in the October 25, 2013 print issue. 

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.8
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
8. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
9. Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award
10. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
11. Sequenom Named to NASDAQ Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... 27, 2015  Ceres, Inc. (Nasdaq: CERE ), ... patent for a genetic sequence derived from soybean, covering ... product development and plant transformation. The company believes that ... that are the target of a class of commercial ... commercial license to the innovation, including an opportunity for ...
(Date:5/27/2015)... MARLBOROUGH, Mass. , May 27, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today provided an update on the status of ... Stock. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... there were 3,085 and 21 shares of Series ...
(Date:5/27/2015)... ­ Caris Life Sciences®, a leading biotechnology ... today announced it has appointed the Levine Cancer Institute, ... site in the Caris Centers of Excellence for Precision ... is one of the largest cancer care providers throughout ... patients annually. Derek Raghavan , M.D., Ph.D., President ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... HARBIN, China , May ... ("China Sky One Medical" or "the Company") (Nasdaq: ... producing over-the-counter drugs in, the People,s Republic of ... Long,Pharmaceutical Company ("Tian Long") subsidiary successfully obtained renewal,of ...
... NEW YORK , May 27 Pfizer Inc. (NYSE: ... to the EMPHASIS-HF trial early on the recommendations of the trial,s ... analysis by the independent Data Safety Monitoring Committee (DSMC) of the ... early according to the protocol pre-defined stopping rules. , ...
... in the College of Engineering at Virginia Tech, has ... to support development of a carbon nanotube-enhanced composite for ... huge wind turbine blades. Powe awards provide seed ... member institutions. These awards are intended to enrich the ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 2Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 4Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 5Powe Award supports development of nanocomposites to monitor wind turbine blade structure 2
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Biological and Environmental Nanotechnology (CBEN) have developed a ... human cell that is programmed to light up ... of particular proteases is a common hallmark of ... the September issue of the journal Biochemical and ...
... The most detailed analysis to date of how humans differ ... that natural selection has shaped the recent evolution of our ... Celera Diagnostics. , In a study published in the ... 11,624 genes, comparing how genes vary not only among 39 ...
... a 'living gel' that could be applied to the ... , The researchers genetically modified bacteria that are normally ... protein that stops the HIV virus from infecting cells. ... the internal body surfaces where HIV transmission can occur ...
Cached Biology News:'Smart' nanoprobes light up disease 2Cornell finds natural selection in humans 2Cornell finds natural selection in humans 3Living anti-HIV gel shows early promise 2